Tildrakizumab (SCH 900222) is a humanized monoclonal antibody selectively targeting the p19 subunit of interleukin-23 (IL-23), a pivotal cytokine in sustaining the Th17 cell phenotype. This antibody exhibits high affinity for the single-chain IL-23, demonstrated by a dissociation constant (Kd) of 136 pM. Clinically, Tildrakizumab has been shown to be effective in the treatment of moderate to severe plaque psoriasis.
Tildrakizumab (SCH 900222) is a humanized monoclonal antibody selectively targeting the p19 subunit of interleukin-23 (IL-23), a pivotal cytokine in sustaining the Th17 cell phenotype. This antibody exhibits high affinity for the single-chain IL-23, demonstrated by a dissociation constant (Kd) of 136 pM. Clinically, Tildrakizumab has been shown to be effective in the treatment of moderate to severe plaque psoriasis.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
